Red X iconGreen tick iconYellow tick icon

Barry HockScientific Officer
Honorary Research Fellow

BSc(Hons), PhD(Otago)

Email barry.hock@otago.ac.nz
Tel +64 3 244 1106

Publications

Gieseg, S., Hock, B., Ogugofor, M., & McCormick, S. (2026). Could chimeric antigen receptor-T cell treatment of atherosclerosis in mice translate to a human therapy? Annals of Translational Medicine, 14(4). Advance online publication. doi: 10.21037/atm-2026-0132 Journal - Research Other

Dobson, L. J., Marron, P. W., Drabble, A. H. T., Liyanage, T. D., Pe, K. C., Slaney, C. Y., Hock, B. D., & McLellan, A. D. (2026). Parallel processing of T cells and natural killer cells to enhance in vivo CAR T cell activity against blood and solid cancers. Clinical & Translational Immunology, 15(9), e70120. doi: 10.1002/cti2.70120 Journal - Research Article

Topham, B. J., Hock, B. D., Wiggins, G. A. R., Ashby, L. V., Magon, N. J., Phillips, E., Symonds, E. K. C., Danielson, K. M., & Currie, M. J. (2026). Priming of human monocytes by β-glucan and obesity-associated factors: Modifications to global DNA methylation, gene expression, phenotype and function. Frontiers in Immunology, 17, 1825431. doi: 10.3389/fimmu.2026.1825431 Journal - Research Article

Dobson, L. J., Hock, B. D., Drabble, A. H. T., Goddard, L., McKenzie, J. L., MacPherson, S. A., & McLellan, A. D. (2026). Enhanced Fc and complement activity of Fc-modified avelumab boosts anti-tumor activity but promotes NK cell fratricide. Clinical & Translational Immunology, 15, e70098. doi: 10.1002/cti2.70098 Journal - Research Article

Hock, B. D., Goddard, L., Dobson, L. J., MacPherson, S. A., O'Donnell, J. L., McKenzie, J. L., & McLellan, A. D. (2025). Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1. Cancer Immunology, Immunotherapy, 74, 216. doi: 10.1007/s00262-025-04078-0 Journal - Research Article

Back to top